PainReform Ltd (NASDAQ:PRFX) announced results from new studies demonstrating the superior in-vitro release (IVR) rates of PRF-110 compared to topical post-surgical pain management products available in the market. These findings underscore PainReform’s commitment to advancing non-opiate pain relief options and mark a significant milestone in developing long-lasting pain management solutions. Leveraging the latest IVR technology, which automates the testing of drug release from formulations over
(Reuters) -Vertex Pharmaceuticals said on Tuesday its experimental non-opioid drug for treating post-surgical pain met the main goal in late stage trials but was not any more effective than some commonly used painkillers. Vertex's drug, "VX-548", works by blocking pain signals at its origin before it reaches the brain. Attempts to bring new opioid alternatives to market by drugmakers such as Eli Lilly and Regeneron Pharmaceuticals have failed in past clinical trials.
Spinal Muscular Atrophy Clinical Trials Insight 2023, Pipeline openpr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from openpr.com Daily Mail and Mail on Sunday newspapers.
Alopecia Areata Market is Predicted to Exhibit Remarkable openpr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from openpr.com Daily Mail and Mail on Sunday newspapers.
Acute Social Anxiety Disorder Market Report 2032: openpr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from openpr.com Daily Mail and Mail on Sunday newspapers.